Biofrontera Inc.
BFRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $37 | $34 | $29 | $24 |
| % Growth | 9.5% | 18.8% | 19% | – |
| Cost of Goods Sold | $19 | $17 | $15 | $13 |
| Gross Profit | $19 | $17 | $13 | $11 |
| % Margin | 50.1% | 48.8% | 47% | 47.1% |
| R&D Expenses | $2 | $0 | $0 | $0 |
| G&A Expenses | $0 | $38 | $36 | $37 |
| SG&A Expenses | $34 | $39 | $36 | $37 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$4 | -$1 |
| Operating Expenses | $36 | $39 | $32 | $37 |
| Operating Income | -$17 | -$23 | -$19 | -$25 |
| % Margin | -46.1% | -66.6% | -64.8% | -104.6% |
| Other Income/Exp. Net | -$1 | $3 | $18 | -$12 |
| Pre-Tax Income | -$18 | -$20 | -$1 | -$38 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$20 | -$1 | -$38 |
| % Margin | -47.6% | -59.1% | -2.2% | -156.5% |
| EPS | -3.22 | -13.02 | -0.61 | -44.1 |
| % Growth | 75.3% | -2,034.4% | 98.6% | – |
| EPS Diluted | -3.22 | -13.02 | -0.61 | -44.1 |
| Weighted Avg Shares Out | 6 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 6 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$14 | -$18 | $1 | -$37 |
| % Margin | -38.7% | -54.2% | 3.3% | -152.5% |